Kit Simpson to Life Expectancy
This is a "connection" page, showing publications Kit Simpson has written about Life Expectancy.
Connection Strength
0.109
-
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
Score: 0.080
-
Design and assessment of cost-effectiveness studies in AIDS populations. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 4:S28-32.
Score: 0.030